Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct;47(10):1173-1183.
doi: 10.1111/imj.13550.

New insights into sinusoidal obstruction syndrome

Andrea Piccin  1   2   3 , Maria T Sartori  4 , Gianni Bisogno  5 , Muriel Van Schilfgaarde  6 , Graziella Saggiorato  4 , Angela M D Pierro  3 , Daisy Corvetta  3 , Luigi Marcheselli  7 , Andrea Mega  3   8 , Günther Gastl  2 , Simone Cesaro  9
Affiliations

New insights into sinusoidal obstruction syndrome

Andrea Piccin et al. Intern Med J. 2017 Oct.

Erratum in

  • Corrigendum.
    [No authors listed] [No authors listed] Intern Med J. 2021 Apr;51(4):627. doi: 10.1111/imj.15305. Intern Med J. 2021. PMID: 33890380 No abstract available.

Abstract

Background: Entry criteria included patients who developed sinusoidal obstruction syndrome (SOS) at a single centre from January 2000 to December 2011. Patients who underwent haemopoietic stem cell transplantation or actinomicyn-based chemotherapy for nephroblastoma were selected. The study group comprised five patients with SOS who were compared with a control group of seven patients without SOS.

Aim: To study the relationships between endothelial extracellular vesicles (EV) and plasminogen-activator inhibitor type 1(PAI-1) to assess their modification in the early phase of SOS.

Methods: Consecutive blood samples were tested for cell-derived EV, PAI-1 and coagulation parameters. Any statistically significant correlation between all datasets was searched.

Results: Antithrombin level and platelet count were statistically significantly reduced in SOS patients, suggesting a consumption status. PAI-1:Ag and PAI-1:act showed an inverse relationship with platelet counts (coef. -0.034, SE = 0.016; P = 0.041 and -0.052, SE = 0.019; P = 0.011 respectively). During follow up, PAI-1:Ag was inversely related to EV CD144+ (coef. -0.261, SE = 0.094; P = 0.007) and antithrombin (coef -0.509, SE = 0.175; P = 0.005). PAI-1:act showed an inverse association with EV CD144+ (coef.-0.251, SE = 0.121; P = 0.043), EV CD31+/CD41+ (coef. -0.004, SE = 0.002; P = 0.026) and antithrombin (coef. -0.470, SE = 0.220; P = 0.038). EV generated by rupture of gap junctions (EV CD144+) were increased in SOS patients and also showed a change over time.

Conclusion: This study demonstrates the existence of an ongoing procoagulant and hypofibrinolytic status in SOS, indicating a possible role for anticoagulant therapy. Moreover, these findings suggest a role for EV CD 144+, either alone or in combination with PAI-1, as a new biomarker for SOS.

Keywords: PAI-1:Ag; PAI-1:act; extracellular vesicle; sinusoidal obstruction syndrome; veno-occlusive disease.

PubMed Disclaimer

References

    1. Czauderna P, Katski K, Kowalczyk J, Kurylak A, Lopatka B, Skotnicka-Klonowicz G et al. Venoocclusive liver disease (SOS) as a complication of Wilms' tumour management in the series of consecutive 206 patients. Eur J Pediatr Surg 2000; 10: 300-3.
    1. Corbacioglu S, Kernan N, Lehmann L, Brochstein J, Revta C, Grupp S et al. Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Expert Rev Hematol 2012; 5: 291-302.
    1. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-22.
    1. Piccaluga PP, Martinelli G, Rondoni M, Malagola M, Gaitani S, Isidori A et al. Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas. Leuk Lymphoma 2004; 45: 1791-5.
    1. Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 2012; 379: 1301-9.

LinkOut - more resources